All In Biotech

Drug Trial Radar · NCT07123779

HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Jan 2029

Study completion Jan 2030

Sponsor

Lead sponsor
35Pharma Inc., a GSK companyIndustry
Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction

Conditions

  • Pulmonary Hypertension
  • Heart Failure With Preserved Ejection Fraction

Interventions

  • HS235Biological

    Subcutaneous Injection

  • PlaceboOther

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Number of Adverse Events (AEs)Time frame: Up to 85 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site-105

    Kansas City, Missouri · Recruiting

  • Investigational Site-101

    Greenville, South Carolina · Recruiting

  • Investigational Site-103

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.